12 January 2026
Boehringer Ingelheim and Jazz Pharmaceuticals Collaborate on HER2-Targeted Breast Cancer Therapy
Phase 1b study to test zongertinib and zanidatamab combo in HER2-positive breast cancer, aiming to improve outcomes with dual HER2-targeted therapy.
